Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.

Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB.

Nat Med. 2019 Sep;25(9):1415-1421. doi: 10.1038/s41591-019-0561-9. Epub 2019 Sep 9.

PMID:
31501609
2.

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS.

JAMA Oncol. 2019 Jul 1;5(7):1020-1027. doi: 10.1001/jamaoncol.2019.0892.

PMID:
31145418
3.

Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.

Wo JY, Plastaras JP, Metz JM, Jiang W, Yeap BY, Drapek LC, Adams J, Baglini C, Ryan DP, Murphy JE, Parikh AR, Allen JN, Clark JW, Blaszkowsky LS, DeLaney TF, Ben-Josef E, Hong TS.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):90-95. doi: 10.1016/j.ijrobp.2019.04.040. Epub 2019 May 22.

PMID:
31128146
4.

High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.

Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AR, Allen JN, Ryan DP, Ting DT, Deshpande V, Wo JY.

Oncologist. 2019 Jun;24(6):e275-e283. doi: 10.1634/theoncologist.2018-0794. Epub 2019 Feb 12.

PMID:
30755500
5.

Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.

Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):64-72. doi: 10.1016/j.ijrobp.2019.01.076. Epub 2019 Jan 23.

PMID:
30684667
6.

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX.

Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.

7.

Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis.

McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, Drapek LC, Goyal L, Blaszkowsky LS, Clark JW, Allen JN, Parikh AR, Ryan DP, Ferrone CR, Tanabe KK, Wolfgang JA, Zhu AX, Hong TS.

Pract Radiat Oncol. 2018 Nov - Dec;8(6):414-421. doi: 10.1016/j.prro.2018.04.012. Epub 2018 Apr 26.

PMID:
29937235
8.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS.

JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329. Erratum in: JAMA Oncol. 2018 Oct 1;4(10):1439.

9.

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.

Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS.

Cancer Med. 2018 May 17. doi: 10.1002/cam4.1558. [Epub ahead of print]

10.

Neuroprotective Role of the Ron Receptor Tyrosine Kinase Underlying Central Nervous System Inflammation in Health and Disease.

Dey A, Allen JN, Fraser JW, Snyder LM, Tian Y, Zhang L, Paulson RF, Patterson A, Cantorna MT, Hankey-Giblin PA.

Front Immunol. 2018 Mar 19;9:513. doi: 10.3389/fimmu.2018.00513. eCollection 2018.

11.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.

Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

12.

Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.

Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR.

Ann Surg. 2019 Apr;269(4):733-740. doi: 10.1097/SLA.0000000000002600.

PMID:
29227344
13.

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.

PMID:
28954285
14.

Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.

Miller CL, Taylor MS, Qadan M, Deshpande V, Worthington S, Smalley R, Collura C, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Parikh AR, Berger D, Tanabe KK, Lillemoe KD, Ferrone CR.

J Gastrointest Surg. 2017 Nov;21(11):1831-1840. doi: 10.1007/s11605-017-3557-0. Epub 2017 Sep 7.

PMID:
28884391
15.

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529.

Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY.

Adv Radiat Oncol. 2017 Feb 6;2(2):110-117. doi: 10.1016/j.adro.2017.01.009. eCollection 2017 Apr-Jun.

16.

Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.

Rose B, Mitra D, Hong TS, Jee KW, Niemierko A, Drapek LN, Blaszkowsky LS, Allen JN, Murphy JE, Clark JW, Ryan DP, Wo JY.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):e291-e297. doi: 10.1016/j.prro.2017.03.008. Epub 2017 Mar 23.

PMID:
28462895
17.

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation.

Allen JN, Dey A, Nissly R, Fraser J, Yu S, Balandaram G, Peters JM, Hankey-Giblin PA.

J Vis Exp. 2017 Apr 3;(122). doi: 10.3791/55445.

18.

The Impact of Pathologic Complete Response in Patients with Neoadjuvantly Treated Locally Advanced Rectal Cancer-a Large Single-Center Experience.

Dinaux AM, Amri R, Bordeianou LG, Hong TS, Wo JY, Blaszkowsky LS, Allen JN, Murphy JE, Kunitake H, Berger DL.

J Gastrointest Surg. 2017 Jul;21(7):1153-1158. doi: 10.1007/s11605-017-3408-z. Epub 2017 Apr 6.

PMID:
28386670
19.

Case 39-2016: A Man with a History of Prostate Cancer and Recent Rectal Bleeding.

Hong TS, Allen JN, Shellito PC.

N Engl J Med. 2017 Mar 2;376(9):898. doi: 10.1056/NEJMc1700703. No abstract available.

PMID:
28273412
20.

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.

Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX.

Cancer. 2017 Jun 1;123(11):1979-1988. doi: 10.1002/cncr.30571. Epub 2017 Feb 13.

21.

Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.

Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS.

Am J Clin Oncol. 2018 Jul;41(7):656-661. doi: 10.1097/COC.0000000000000349.

PMID:
28134673
22.

Case 39-2016. A 74-Year-Old Man with Rectal Bleeding and a History of Prostate Cancer.

Hong TS, Gray PJ, Allen JN, Shellito PC, Lowry KP, Zukerberg LR.

N Engl J Med. 2016 Dec 22;375(25):2481-2488. doi: 10.1056/NEJMcpc1613458. No abstract available.

PMID:
28002705
23.

Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.

Keane FK, Wo JY, Ferrone CR, Clark JW, Blaszkowsky LS, Allen JN, Kwak EL, Ryan DP, Lillemoe KD, Fernandez-Del Castillo C, Hong TS.

Am J Clin Oncol. 2018 Jun;41(6):607-612. doi: 10.1097/COC.0000000000000336.

PMID:
27740973
24.

The Ron Receptor Tyrosine Kinase Regulates Macrophage Heterogeneity and Plays a Protective Role in Diet-Induced Obesity, Atherosclerosis, and Hepatosteatosis.

Yu S, Allen JN, Dey A, Zhang L, Balandaram G, Kennett MJ, Xia M, Xiong N, Peters JM, Patterson A, Hankey-Giblin PA.

J Immunol. 2016 Jul 1;197(1):256-65. doi: 10.4049/jimmunol.1600450. Epub 2016 May 27.

25.

Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.

Rose BS, Jee KW, Niemierko A, Murphy JE, Blaszkowsky LS, Allen JN, Lee LK, Wang Y, Drapek LC, Hong TS, Wo JY.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):747-54. doi: 10.1016/j.ijrobp.2015.12.006. Epub 2015 Dec 17.

PMID:
26972647
26.

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX.

J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14.

27.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX.

Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.

28.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

29.

A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors.

Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX.

Pract Radiat Oncol. 2014 Sep-Oct;4(5):316-322. doi: 10.1016/j.prro.2013.10.002. Epub 2013 Nov 22.

30.

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX.

Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24.

31.

Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control.

Wo JY, Childs SK, Szymonifka J, Mamon HJ, Ryan DP, Blaszkowsky LS, Kwak EL, Ferrone CR, Allen JN, Zhu AX, Wolpin BM, Chan JA, Abrams TA, McCleary NJ, Fernandez-Del Castillo C, Hong TS.

Pract Radiat Oncol. 2014 Mar-Apr;4(2):e117-e123. doi: 10.1016/j.prro.2013.07.006. Epub 2013 Aug 9.

PMID:
24890357
32.

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.

Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):830-8. doi: 10.1016/j.ijrobp.2014.03.034. Epub 2014 May 24.

33.

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.

Cancer. 2014 May 15;120(10):1482-90. doi: 10.1002/cncr.28599. Epub 2014 Feb 5.

34.

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.

Clin Cancer Res. 2014 Apr 1;20(7):1884-90. doi: 10.1158/1078-0432.CCR-13-2649. Epub 2014 Jan 29.

35.

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.

Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, Kwak EL, Mamon HJ, Allen JN, Vasudev E, Shellito PC, Cusack JC, Berger DL, Hong TS.

Ann Oncol. 2014 Jan;25(1):121-6. doi: 10.1093/annonc/mdt516.

36.

Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.

Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS.

J Gastrointest Cancer. 2014 Mar;45(1):34-9. doi: 10.1007/s12029-013-9546-y.

37.

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS.

Oncologist. 2013;18(5):543-8. doi: 10.1634/theoncologist.2012-0435. Epub 2013 May 8.

38.

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.

Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS.

Oncologist. 2013;18(4):377-8. doi: 10.1634/theoncologist.2012-0378. Epub 2013 Apr 11.

39.

Update on eosinophilic lung diseases.

Bhatt NY, Allen JN.

Semin Respir Crit Care Med. 2012 Oct;33(5):555-71. Epub 2012 Sep 21.

PMID:
23001808
40.

Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR.

Ann Surg. 2013 Apr;257(4):731-6. doi: 10.1097/SLA.0b013e318263da2f.

PMID:
22968073
41.

Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.

Arvold ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e337-43. doi: 10.1016/j.ijrobp.2011.12.068. Epub 2012 Mar 11.

PMID:
22414286
42.

Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.

Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, Allen JN, Clark JW, Wadlow RC, Zhu AX, Fernandez-Del Castillo C, Hong TS.

Cancer. 2012 Jun 15;118(12):3026-35. doi: 10.1002/cncr.26633. Epub 2011 Oct 21.

43.

Perioperative steroids for minimizing edema and ecchymosis after rhinoplasty: a meta-analysis.

Hatef DA, Ellsworth WA, Allen JN, Bullocks JM, Hollier LH Jr, Stal S.

Aesthet Surg J. 2011 Aug;31(6):648-57. doi: 10.1177/1090820X11416110. Review.

PMID:
21813878
44.

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.

Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV.

Lancet Oncol. 2010 Jan;11(1):48-54. doi: 10.1016/S1470-2045(09)70333-X. Epub 2009 Nov 20.

PMID:
19932054
45.

A 36-year-old woman with a history of dextrocardia and dyspnea. Diagnosis: unilateral absence of a pulmonary artery (UAPA) with right hypoplastic lung.

Devulapally KK, Bhatt N, Allen JN.

Respiration. 2010;79(1):81-4. doi: 10.1159/000232393. Epub 2009 Jul 31. No abstract available.

46.

Cough, dyspnea, and reticulonodular opacities in a 58-year-old smoker.

Green MB, Allen JN.

Chest. 2007 Aug;132(2):700-3. No abstract available.

PMID:
17699144
47.

The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease.

Magro CM, Ross P, Marsh CB, Allen JN, Liff D, Knight DA, Waldman WJ, Cowden DJ.

Am J Clin Pathol. 2007 Feb;127(2):237-47.

PMID:
17210529
48.
49.

Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies.

Magro CM, Waldman WJ, Knight DA, Allen JN, Nadasdy T, Frambach GE, Ross P, Marsh CB.

Hum Immunol. 2006 Apr-May;67(4-5):284-97. Epub 2006 Apr 5.

PMID:
16720208
50.

The eosinophilic pneumonias.

Allen JN, Magro CM, King MA.

Semin Respir Crit Care Med. 2002 Apr;23(2):127-34.

PMID:
16088605

Supplemental Content

Loading ...
Support Center